Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 9, 2014, Pages 2122-2128

  Masola, Valentina ^a,b   Zaza, Gianluigi ^a   Secchi, Maria Francesca ^b   Gambaro, Giovanni ^c   Lupo, Antonio ^a   Onisto, Maurizio ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Epithelial mesenchymal transition; Heparanase; Renal fibrosis; TGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; FIBROBLAST GROWTH FACTOR 2; HEPARANASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; AUTOCRINE EFFECT; BIOSYNTHESIS; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STIMULUS RESPONSE;

EPITHELIAL-MESENCHYMAL TRANSITION; HEPARANASE; RENAL FIBROSIS; TGF-Β;

ACTINS; ANIMALS; AUTOCRINE COMMUNICATION; BIOLOGICAL MARKERS; CELL LINE; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; KIDNEY; MATRIX METALLOPROTEINASE 9; MESODERM; MICE; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

EID: 84903135790     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.06.005     Document Type: Article

References (32)

1. Hewitson T.D. Renal tubulointerstitial fibrosis: common but never simple. Am. J. Physiol. Renal Physiol. Jun 2009, 296(6):F1239-F1244.
2. Mason R.M., Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. May 2003, 14(5):1358-1373.
3. Kanasaki K., Taduri G., Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front. Endocrinol. (Lausanne) Feb 6 2013, 4:7.
4. Piera-Velazquez S., Li Z., Jimenez S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. Sep 2011, 179(3):1074-1080.
5. Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr. Opin. Nephrol. Hypertens. Jan 2003, 12(1):25-29.
6. Purushothaman A., Chen L., Yang Y., Sanderson R.D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. Nov 21 2008, 283(47):32628-32636.
7. Boor P., Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin. Exp. Pharmacol. Physiol. 2011, 38(7):441-450.
8. Hills C.E., Squires P.E. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. Jun 2011, 22(3):131-139.
9. Strutz F., Zeisberg M., Ziyadeh F.N., Yang C.Q., Kalluri R., Müller G.A., Neilson E.G. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. May 2002, 61(5):1714-1728.
10. Tian Y.C., Chen Y.C., Chang C.T., Hung C.C., Wu M.S., Phillips A., Yang C.W. Epidermal growth factor and transforming growth factor-beta1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp. Cell Res. Jul 1 2007, 313(11):2367-2377. (Epub 2007 Mar 30).
11. Ge S., Zeng R., Luo Y., Liu L., Wei H., Zhang J., Zhou H., Xu G. Role of protein kinase C in advanced glycation end products-induced epithelial-mesenchymal transition in renal proximal tubular epithelial cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. Jun 2009, 29(3):281-285.
12. Ibrini J., Fadel S., Chana R.S., Brunskill N., Wagner B., Johnson T.S., El Nahas A.M. Albumin-induced epithelial mesenchymal transformation. Nephron Exp. Nephrol. 2012, 120(3):e91-e102.
13. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38(12):2018-2039.
14. Garsen M., Rops A.L., Rabelink T.J., Berden J.H., van der Vlag J. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant. 2014, 29(1):49-55.
15. van den Hoven M.J., Rops A.L., Vlodavsky I., Levidiotis V., Berden J.H., van der Vlag J. Heparanase in glomerular diseases. Kidney Int. Sep 2007, 72(5):543-548.
16. Masola V., Maran C., Tassone E., Zin A., Rosolen A., Onisto M. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer Aug 28 2009, 9:304.
17. Zong F., Fthenou E., Wolmer N., Hollósi P., Kovalszky I., Szilák L., Mogler C., Nilsonne G., Tzanakakis G., Dobra K. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS ONE Oct 5 2009, 4(10):e7346.
18. Reiland J., Kempf D., Roy M., Denkins Y., Marchetti D. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia Jul 2006, 8(7):596-606.
19. Masola V., Gambaro G., Tibaldi E., Onisto M., Abaterusso C., Lupo A. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim. Biophys. Acta Aug 2011, 1813(8):1475-1482.
20. Masola V., Gambaro G., Tibaldi E., Brunati A.M., Gastaldello A., D'Angelo A., Onisto M., Lupo A. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J. Biol. Chem. Jan 6 2012, 287(2):1478-1488.
21. Masola V., Onisto M., Zaza G., Lupo A., Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J. Transl. Med. Oct 24 2012, 10:213.
22. Gambaro G., van der Woude F.J. Glycosaminoglycans: use in treatment of diabetic nephropathy. J. Am. Soc. Nephrol. Feb 2000, 11(2):359-368.
23. Ferro V., Hammond E., Fairweather J.K. The development of inhibitors of heparanase, a key enzyme involved in tumor metastasis, angiogenesis and inflammation. Mini Rev. Med. Chem. Aug 2004, 4(6):693-702.
24. Gil N., Goldberg R., Neuman T., Garsen M., Zcharia E., Rubinstein A.M., van Kuppevelt T., Meirovitz A., Pisano C., Li J.P., van der Vlag J., Vlodavsky I., Elkin M. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes Jan 2012, 61(1):208-216.
25. Vandooren J., Geurts N., Martens E., Van den Steen P.E., Opdenakker G. Zymography methods for visualizing hydrolytic enzymes. Nat. Methods Mar 2013, 10(3):211-220.
26. Lan H.Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 2011, 7(7):1056-1067.
27. Hills C.E., Squires P.E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am. J. Nephrol. 2010, 31(1):68-74.
28. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. Feb 2009, 19(2):156-172.
29. Hayashi H., Sakai T. Biological significance of local TGF-β activation in liver diseases. Front. Physiol. Feb 6 2012, 3:12.
30. Yang J., Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol. Oct 2001, 159(4):1465-1475.
31. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. Jan 2009, 19(1):128-139.
32. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. May 2013, 280(10):2294-2306.